Foghorn Therapeutics (FHTX) Change in Accured Expenses (2019 - 2026)

Foghorn Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 85.21% year-over-year to -$4.5 million; the TTM figure through Mar 2026 stood at $153000.0 (up 193.87% YoY), while the FY2025 annual figure was $2.2 million, up 490.78% from the prior year.
• Change in Accured Expenses was -$4.5 million for Q1 2026 at Foghorn Therapeutics, down from $1.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.0 million in Q3 2024 to a low of -$4.5 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$186705.9 across 5 years, with a median of $332000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses sank 829.22% in 2024, then jumped 764.14% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $894000.0 in 2022, then slumped by 62.86% to $332000.0 in 2023, then tumbled by 829.22% to -$2.4 million in 2024, then soared by 159.27% to $1.4 million in 2025, then slumped by 410.66% to -$4.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.5 million (Q1 2026), $1.4 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.